rich 1.0 Action Network https://actionnetwork.org <link href='https://actionnetwork.org/css/style-embed-v3.css' rel='stylesheet' type='text/css' /><script src='https://actionnetwork.org/widgets/v6/letter/xtandi?format=js&source=widget'></script><div id='can-letter-area-xtandi' style='width: 100%'><!-- this div is the target for our HTML insertion --></div> Drug Prices are Too High https://actionnetwork.org/groups/drug-prices-are-too-high https://can2-prod.s3.amazonaws.com/share_options/facebook_images/000/345/755/original/Xtandi_Drugs.jpeg We agree with President Biden that it’s wrong when leukemia and lymphoma patients pay much higher costs for the same medication than people living in other countries. That is why we are demanding that the Biden administration allow the generic manufacturing of Xtandi, a highly effective medication used to treat prostate cancer. The National Institutes of Health (NIH) is expected to decide shortly on the fate of a petition demanding that the Biden administration allow generic manufacturing of Xtandi. The NIH needs to hear from you today. Here is a sample comment that you can send the National Institutes of Health (NIH): This case is about whether the government of the United States will use its existing authority under the law to stop Big Pharma from price gouging American prostate cancer patients. Not only that, this case is about whether the U.S. government is prepared to use its existing authority under the law to stop Big Pharma from maintaining outrageously high prescription drug prices at all. You must take a stand that publicly making a drug available at any price is not “reasonable” when Americans pay up to five times more for the same medication as patients living in other countries, especially when American taxpayers funded the grants which led to its discovery. If you do not act to allow the generic manufacturing of Xtandi, it will be clear that you are handing Big Pharma a blank check to continue price gouging American patients. https://actionnetwork.org/letters/xtandi